Medical Technology

@xconomy.com 3 years ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Disc Medicine Launches With $50M to Advance New Anemia Treatments

@xconomy.com 5 years ago

FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

@xconomy.com 5 years ago

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

@xconomy.com 5 years ago

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine